Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
Andreas Rimner, W. Victoria Lai, Raffaele Califano, Salma K. Jabbour, Charles M. Rudin, Corinne Faivre‐Finn, Byoung Chul Cho, Terufumi Kato, Jinming Yu, Wyatt Chafin, Li Yu, Bin Zhao, Lauren A. Byers
Topics & Concepts
PembrolizumabMedicineInternal medicineOncologyLung cancerPlaceboDurvalumabOlaparibCarboplatinPopulationClinical endpointChemoradiotherapyRandomized controlled trialRadiation therapyCancerChemotherapyCisplatinPathologyImmunotherapyAlternative medicineEnvironmental healthBiochemistryPolymeraseChemistryGenePoly ADP ribose polymeraseLung Cancer Research StudiesCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations